Ранний рак молочной железы.Различные аспекты комбинированного лечения. Новые подходы к неоадъювантной терапии раннего HER2 позитивного рака молочной железы

Ранний рак молочной железы.Различные аспекты комбинированного лечения. Новые подходы к неоадъювантной терапии раннего HER2 позитивного рака молочной железы

Автор: Сакаева Дина Дамировна

Журнал: Злокачественные опухоли @malignanttumors

Рубрика: Диагностика и лечение опухолей. Состояние проблемы

Статья в выпуске: 1 (5), 2013 года.

Бесплатный доступ

Опыт применения препаратов, блокирующих HER2-рецепторы, в клинической практике насчитывает около 15 лет. За это время произошла серьезная эволюция наших представлений о месте и показаниях к назначению этих препаратов при HER2-позитивном раке молочной железы. Доказано, что неоадъювантная таргетная терапия раннего HER2-позитивного рака молочной железы уменьшает риск рецидивирования и метастазирования. Тем не менее, блокирование HER2-рецепторов при раннем раке молочной железы оставляет множество открытых вопросов.Применение таргетных препаратов в неоадъювантном режиме является перспективным и требует продолжения исследований.

Her2-позитивный рак молочной железы, неоадъювантная терапия

Короткий адрес: https://sciup.org/14045444

IDR: 14045444

Список литературы Ранний рак молочной железы.Различные аспекты комбинированного лечения. Новые подходы к неоадъювантной терапии раннего HER2 позитивного рака молочной железы

  • Bear H. D. Indications for neoadjuvant chemotherapy for breast cancer. Semin. Oncol. -1998; 25: 3
  • Hortobagyi G. N., Blumenschein G. R., Spanos W. et al. Multimodal treatment of locoregionally advanced breast Cancer. Cancer. -1983; 51: 763
  • Hortobagyi G. N., Ames F. C., Buzdar A. U. et al. Management of stage III primary breast Cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. -1988; 62: 2507
  • Hortobagyi G. N. Comprehensive management of locally advanced breast Cancer.Cancer. -1990; 66: 1387
  • Fisher B., Bryant J., Wolmark N. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. -1998; 16: 2672
  • Wolmark N., Wang J., Mamounas E. et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. -2001; 30: 96-102
  • Bear H. D., Anderson S., Brown A. et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. -2003; 21: 4165-4174
  • Van der Hage J. A., van de Velde C. J. H, Julien J-P et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. -2001; 19:4224-4237
  • Mieog S., van der Hage J., van de Velde C. J. H. Preoperative Chemotherapy for Women with Operable Breast Cancer (Review) 1. John Wiley & Sons, Ltd. January 24 , DOI: CD005002 DOI: 10.1002/14651858
  • Kuerer H. M., Newman L. A., Smith T. M. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. -1999;17: 460-469
  • Guarneri V., Broglio K., Kau S-W et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol. -2006; 24: 1037-1044
  • von Minckwitz G., Kaufmann M., Kmmel S. et al. Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane +/-trastuzumab containing chemotherapy. Cancer Res. -2009; 69 (suppl.): 79
  • Ring A. E., Smith I. E., Ashley S. et al. Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer. -2004; 91: 2012-2017
  • Colleoni M. Preoperative systemic treatment: Prediction of responsiveness. Breast 2003; 12 (suppl 1, abstr S35): S13
  • Esserman L. J., Perou C., Cheang M. et al. Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657). ASCO Meeting Abstracts, 2009 (LBA515)
  • Slamon D. J., Leyland-Jones B., Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. -2001; 344: 783
  • Pritchard K. I., Messersmith H., Elavathil L. et al. HER2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol. -2008; 26: 736-744
  • Di Leo A., Desmedt C., Bartlett J. M. S. et al. HER2 and TOP2A as predictive markers for anthracycline containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol. -2011;12: 1134-1142
  • Hayes D. F., Thor A. D., Dressler L. G. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. -2007; 357: 1496-1506
  • Kaufmann M., von Minckwitz G., Bear H. D. et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. -2007; 18:1927-1934
  • Buzdar A. U., Ibrahim N. K., Francis D. et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermalgrowth factor receptor 2-positive operable breast cancer. J Clin Oncol. -2005; 23:3676-3685
  • Buzdar A. U., Valero V., Ibrahim N. K. et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor-2 positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. -2007;13: 228-233
  • Gianni L., Eiermann W., Semiglazov V. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet. -2010; 375: 377-384
  • Untch M., Rezai M., Loibl S. et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. -2010; 28: 2024-2031
  • von Minckwitz G., Rezai M., Loibl S. et al. Capecitabine in addition to anthracycline-and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncolм 2010; 28:2015-2023
  • Семенова А. И. Основные принципы системной терапии позитивного рака молочной железы. Практическая онкология. -Т.11. -№4. -2010. -с. 239-246
  • Jobnston S., Trudeau M., Kaufman B. еt al Phase II study of predictive biomarker profails for response targeting human epidermal growth factor receptor 2 (HER2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol. -2008; 26: 1066-1072
  • Baselga J., Bradbury I., Eidtmann H. et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet. -2012; 379: 633-640
  • Untch M., Loibl S., Bischoff J. et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG44): a randomised phase 3 trial. Lancet Oncol. -2012; 13: 135-144
  • Guarneri V., Frassoldati A., Bottini A. et al. Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol. -2012; 30: 1989-1995
  • Gianni L., Pienkowski T., Im Y-H et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study (‘NeoSphere’). Cancer Res. -2010; 70 (24 Suppl.): Abstr S3-2
  • Baselga J., Corts J., Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. -2012; 366: 2
  • Blackwell K. L., Burstein H. J., Storniolo A. M. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. -2010; 28
  • Sousa B., Cardoso F. Neoadjuvant treatment for HER2-positiv and tripl-negativ breast cancer. Ann Oncol. -2012; 23: 237-242
Еще
Статья научная
SciUp 2024 © 2024 ©